American Well Corporation reports developments for Amwell, a SaaS-based software platform for technology-enabled healthcare used by payers and health systems. Company updates center on quarterly and annual operating results, business reviews, investor conference participation, and equity-compensation actions such as inducement-plan grants.
The Amwell platform combines software and services that support virtual care programs across the care continuum, including virtual primary care, urgent care, clinical partner programs, scheduling, provider workflows, prescribing, and treatment-guideline reference tools. News about AMWL commonly connects these platform capabilities with payer and health system relationships, partner clinical programs, and management commentary on technology-enabled care delivery.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Amwell (NYSE: AMWL) will report its first-quarter 2023 operating results on May 3, 2023, at 5 p.m. Eastern time. Following the earnings release, the management team will host a live conference call to discuss results and provide updates.
Investors can access the live audio webcast on the Amwell Investors website or dial in at (888) 510-2008 for U.S. listeners and (646) 960-0306 internationally. The conference ID is 7830032, with a replay available for 90 days post-call.
Amwell is a leader in digital healthcare, with a platform used by over 2,000 hospitals and covering over 80 million lives. The company aims to enhance healthcare access and quality through digital solutions, supporting various care types.
DarioHealth Corp. (Nasdaq: DRIO) has entered into a strategic partnership with Amwell (NYSE: AMWL), integrating Dario's cardiometabolic solutions into Amwell's digital care delivery platform, which covers over 90 million lives. This collaboration aims to enhance the care experience for individuals with conditions such as diabetes and hypertension by providing access to Dario's personalized digital health solutions. The Dario cardiometabolic suite will be available to Amwell customers in the second half of 2023, promoting a seamless member journey and supporting better health management.
Amwell (NYSE: AMWL) has announced the launch of its new cardiometabolic program, enhancing its ecosystem of digital health solutions to better serve members with chronic diseases like diabetes and high blood pressure. This initiative, in partnership with DarioHealth (Nasdaq: DRIO), integrates Dario's personalized digital therapeutic solutions into the Amwell platform, facilitating seamless referrals for clinicians. The program aims to improve health outcomes by ensuring continuous care and engagement for over one-third of Americans living with metabolic conditions. Through connected devices and coaching, members experience a holistic approach to managing their health.